REPLICor 公司网站上的REP 9AC 消息2010年11月30日

ybdn

REPLICor 公司网站英文版首页网址如下：http://www.replicor.com/debut_anglais2.htm 下面是在首页里该公司的自我介绍：
REPLICor is a biopharmaceutical company developing a new antiviral drug that will revolutionize the treatment of patients with chronic hepatitis B and for patients with chronic hepatitis C undergoing liver transplantation. This antiviral drug is currently being tested in a clinical trial in Asia to demonstrate its safety and activity in human patients. It is expected that our drug will also find important applications in the treatment of patients infected with chronic hepatitis C, influenza, RSV and CMV.
(REPLICor是一家生物制药公司开发一种新的抗病毒的药物，将彻底改变与慢性乙型肝炎和慢性丙型肝炎患者接受肝移植患者的治疗。这种抗病毒的药物，目前正在测试在临床试验中证明亚洲在人类患者的安全和活动。预计，我们的药物也将发现，在与慢性丙型肝炎，流行性感冒，呼吸道合胞病毒和黄瓜花叶病毒感染者的治疗有重要应用。)
在后面的表格上，我们可以看到这种乙肝药物正处在Phase I / II，从他们的介绍看应该是在亚洲进行Phase I 。


从这个网页可以看到REP 9AC很有希望成功，至少是当前该公司把这个药当作主打的拳头产品，可以说完全押宝在这个药上面。而以前我也到这个公司网站上看过，影响里是提到了这种药，该公司自认为离实用还很早。现在不一样了，公司的态度很亢奋，声称要把这类东西用到多种病毒的治疗上。

与战友们分享我见到这些信息后的快乐！

渺小渺

从这个网页可以看到REP 9AC很有希望成功，至少是当前该公司把这个药当作主打的拳头产品，可以说完全押宝在这个药上面。而以前我也到这个公司网站上看过，印象里是提到了这种药，该公司自认为离实用还很早。现在不一样了，公司的态度很亢奋，声称要把这类东西用到多种病毒的治疗上

谢谢，主页上细微的变化都被你发现了，又给了我们一丝希望，真羡慕你英文好

梦人

REP 9AC  值得期待！

batibaby

http://www.replicor.com/debut_anglais2.htm

Hepatitis B



There are 400 million hepatitis B (HBV) patients worldwide.  It is estimated that about 100 million of these patients will eventually die from complications directly related to their chronic HBV infection despite available therapies. Current therapies have been associated with several problems including viral resistance, significant toxicities and the lack of a curative response even after many years of therapy.



Our drug is a first-in-class surface antigen release inhibitor. It prevents the release of a viral protein called surface antigen from infected liver cells (hepatocytes). Mounting evidence is now showing that surface antigen acts to suppress the immune response to HBV infection and may allow the infection to be chronically maintained in the liver. The administration of our drug to animals or humans results in a rapid reduction and elimination of surface antigen in the blood. This reduction is associated with a restoration of the immune system’s capability to fight the infection as demonstrated by the development of antibodies against surface antigen. In other words, the removal of surface antigen from the blood gives patients the ability to successfully fight their infection on their own. In addition, because of its mechanism of action, the development of resistance to our drug is very unlikely.



In collaboration with scientists from the University of Adelaide, Australia, REPLICor has tested the antiviral potential of its drug in ducks infected with duck hepatitis B viruses, a recognized animal model that is a good predictor of antiviral activity in human subjects. We have shown that a 4 week daily treatment regimen with our drug was able to result in a curative response in more than half of DHBV-infected ducks treated.  This is the first time any such curative response has been achieved in this model and has not been achievable with drugs currently marketed for the treatment of HBV.



Interim clinical data from our phase I/II trial shows that our drug is well tolerated and has substantial antiviral activity in patients suffering from chronic HBV infection.  The administration of our drug results in the rapid elimination of surface antigen and the appearance of antibodies in most patients. This is followed by a substantial reduction of viral DNA titers.


Rep9AC 声称他们的临床1期和二期的数据表明此药具有很好的耐受性，这些数据如果不是先前论文中提到的那6个人的话，是不是会有official report？要是有的话并且不是商业机密的话，哪位英文大仙给他们发邮件索要一份吧。

hatecccdna

旧闻了。。。
哎

苹苹苹

有懂英文的战友可以与这家公司联系一下,希望能早日用于临床,造福患者.

逝水有声

回复 苹苹苹 的帖子

这个药有希望清除肝脏内的病毒吗？

逝水有声

这个药有希望清除肝脏内的病毒吗

batibaby

回复 逝水有声 的帖子

别的不说，它能清除表面抗原，至少是一个作弊的良药。

逝水有声

回复 batibaby 的帖子

呵呵，有道理，但是我们的目标不是只为了作弊啊！